Wanbangde Pharmaceutical Holding Group Co., Ltd. (SHE:002082)
China
· Delayed Price · Currency is CNY 19.57
+0.91 (4.88%)
Mar 10, 2026, 3:04 PM CST
SHE:002082 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 1,370 | 1,427 | 1,531 | 1,770 | 1,923 | 13,678 | Upgrade
|
| Other Revenue | 16.11 | 16.11 | 10.51 | 16.46 | 7.86 | 23.67 | Upgrade
|
| Revenue | 1,387 | 1,443 | 1,542 | 1,786 | 1,931 | 13,702 | Upgrade
|
| Revenue Growth (YoY) | -13.26% | -6.39% | -13.69% | -7.47% | -85.91% | -17.91% | Upgrade
|
| Cost of Revenue | 897.71 | 847.18 | 918.18 | 852.57 | 999.27 | 12,364 | Upgrade
|
| Gross Profit | 488.87 | 596.19 | 623.76 | 933.85 | 931.33 | 1,338 | Upgrade
|
| Selling, General & Admin | 365.01 | 443.02 | 458.13 | 579.71 | 571.77 | 672.45 | Upgrade
|
| Research & Development | 66.88 | 59.87 | 53.98 | 59.1 | 76.2 | 184.89 | Upgrade
|
| Other Operating Expenses | 45.29 | 19.42 | 17.89 | 23.48 | 20.43 | 22.7 | Upgrade
|
| Operating Expenses | 474.65 | 521.42 | 553.57 | 701.27 | 720.65 | 899.44 | Upgrade
|
| Operating Income | 14.21 | 74.77 | 70.19 | 232.58 | 210.69 | 438.07 | Upgrade
|
| Interest Expense | -37.39 | -38.5 | -46.48 | -33.2 | -35.6 | -56.68 | Upgrade
|
| Interest & Investment Income | 18.74 | 18.97 | 5.19 | 10.75 | 235.76 | 18.47 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.05 | -0.05 | -4.53 | -0.82 | -0.93 | 1.81 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.62 | -1.84 | -1.41 | -0.74 | -1.27 | -8.69 | Upgrade
|
| EBT Excluding Unusual Items | -1.87 | 53.35 | 22.96 | 208.58 | 408.65 | 392.98 | Upgrade
|
| Impairment of Goodwill | - | - | - | -67.78 | -19.27 | -74.4 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.88 | 2.94 | -1.83 | -0.56 | -2.39 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -10.88 | 15.74 | 0.12 | -0.95 | -1.21 | -0.31 | Upgrade
|
| Asset Writedown | -23.14 | -21.75 | -2.88 | -22.5 | -28.09 | -1.97 | Upgrade
|
| Other Unusual Items | 56.05 | 8.68 | 11.56 | -16.66 | 3.46 | 31.45 | Upgrade
|
| Pretax Income | 24.04 | 58.95 | 29.93 | 100.13 | 361.14 | 347.76 | Upgrade
|
| Income Tax Expense | 13.76 | 13.71 | 3.6 | 26.43 | 199.98 | 55.54 | Upgrade
|
| Earnings From Continuing Operations | 10.29 | 45.25 | 26.33 | 73.71 | 161.16 | 292.21 | Upgrade
|
| Minority Interest in Earnings | 3.92 | 10.19 | 22.88 | 19.55 | 5.35 | -7.28 | Upgrade
|
| Net Income | 14.2 | 55.44 | 49.21 | 93.26 | 166.51 | 284.94 | Upgrade
|
| Net Income to Common | 14.2 | 55.44 | 49.21 | 93.26 | 166.51 | 284.94 | Upgrade
|
| Net Income Growth | -86.06% | 12.67% | -47.23% | -43.99% | -41.56% | -3.26% | Upgrade
|
| Shares Outstanding (Basic) | 488 | 616 | 615 | 622 | 617 | 606 | Upgrade
|
| Shares Outstanding (Diluted) | 488 | 616 | 615 | 622 | 617 | 606 | Upgrade
|
| Shares Change (YoY) | -21.16% | 0.15% | -1.06% | 0.82% | 1.73% | 21.45% | Upgrade
|
| EPS (Basic) | 0.03 | 0.09 | 0.08 | 0.15 | 0.27 | 0.47 | Upgrade
|
| EPS (Diluted) | 0.03 | 0.09 | 0.08 | 0.15 | 0.27 | 0.47 | Upgrade
|
| EPS Growth | -82.32% | 12.50% | -46.67% | -44.44% | -42.55% | -20.34% | Upgrade
|
| Free Cash Flow | -258.26 | 23.11 | -201.59 | -406.88 | -263.42 | -408.24 | Upgrade
|
| Free Cash Flow Per Share | -0.53 | 0.04 | -0.33 | -0.65 | -0.43 | -0.67 | Upgrade
|
| Dividend Per Share | - | - | 0.080 | 0.120 | - | 0.200 | Upgrade
|
| Dividend Growth | - | - | -33.33% | - | - | 33.33% | Upgrade
|
| Gross Margin | 35.26% | 41.30% | 40.45% | 52.28% | 48.24% | 9.76% | Upgrade
|
| Operating Margin | 1.03% | 5.18% | 4.55% | 13.02% | 10.91% | 3.20% | Upgrade
|
| Profit Margin | 1.02% | 3.84% | 3.19% | 5.22% | 8.63% | 2.08% | Upgrade
|
| Free Cash Flow Margin | -18.63% | 1.60% | -13.07% | -22.78% | -13.64% | -2.98% | Upgrade
|
| EBITDA | 111.26 | 170.42 | 163.98 | 337.3 | 305.12 | 545.18 | Upgrade
|
| EBITDA Margin | 8.02% | 11.81% | 10.63% | 18.88% | 15.80% | 3.98% | Upgrade
|
| D&A For EBITDA | 97.04 | 95.65 | 93.79 | 104.72 | 94.43 | 107.11 | Upgrade
|
| EBIT | 14.21 | 74.77 | 70.19 | 232.58 | 210.69 | 438.07 | Upgrade
|
| EBIT Margin | 1.03% | 5.18% | 4.55% | 13.02% | 10.91% | 3.20% | Upgrade
|
| Effective Tax Rate | 57.22% | 23.25% | 12.04% | 26.39% | 55.37% | 15.97% | Upgrade
|
| Revenue as Reported | 1,387 | 1,443 | 1,542 | 1,786 | 1,931 | 13,702 | Upgrade
|
| Advertising Expenses | - | 1.49 | 3.73 | 1.32 | 4.86 | 3.81 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.